Document Detail

A comprehensive review of the long-term and short-term treatment of melasma with a triple combination cream.
MedLine Citation:
PMID:  16901182     Owner:  NLM     Status:  MEDLINE    
Melasma is a common disorder of hyperpigmentation and generally involves areas of the face and neck. Hyperpigmentation is especially prevalent in darker complected patients and is often difficult to treat. Hydroquinone, tretinoin, and topical corticosteroids are well established monotherapeutic agents for treating melasma and hyperpigmentation; however, a stable, once-daily formulation triple combination cream containing 0.05% tretinoin, 4.0% hydroquinone, and 0.01% fluocinolone acetonide (Tri-Luma) represents the only commercially available combination of all three agents. This product is approved by the US FDA for the treatment of facial melasma. A number of publications have described the safety and efficacy of triple combination cream in over 2000 patients with melasma, some of whom were treated for >12 months. In the initial 8-week study, 29% of patients experienced complete clearing of melasma by week 8, and 77% were clear or almost clear by week 8. Similarly, good results were seen in the two long-term studies, with the clear/mild rate ranging from 78% to 84% of patients at month 6 and from 81% to 94% of patients at month 12. Adverse events were almost always mild in severity and typically occurred only at the application site. The primary concern for most physicians using corticosteroid-containing products on the face is skin atrophy. However, only two cases of skin atrophy were reported across the three published studies. Overall, the results of these extensive studies indicate that triple combination cream is efficacious in treating melasma and exhibits a safe profile with low potential for adverse events.
Helen M Torok
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  American journal of clinical dermatology     Volume:  7     ISSN:  1175-0561     ISO Abbreviation:  Am J Clin Dermatol     Publication Date:  2006  
Date Detail:
Created Date:  2006-08-11     Completed Date:  2006-12-15     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  100895290     Medline TA:  Am J Clin Dermatol     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  223-30     Citation Subset:  IM    
Trillium Creek Dermatology Center, Medina, Ohio 44526, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Cutaneous
Fluocinolone Acetonide / pharmacology*
Glucocorticoids / pharmacology
Hydroquinones / pharmacology*
Keratolytic Agents / pharmacology
Melanosis / drug therapy*
Time Factors
Tretinoin / pharmacology*
Reg. No./Substance:
0/Glucocorticoids; 0/Hydroquinones; 0/Keratolytic Agents; 123-31-9/hydroquinone; 302-79-4/Tretinoin; 67-73-2/Fluocinolone Acetonide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Next Document:  Pharmionics in dermatology: a review of topical medication adherence.